Remove 2011 Remove Networking Remove Safety
article thumbnail

Are timely access and robust safety mutually exclusive?

pharmaphorum

And how can regulators balance timely access with robust safety? A European Federation of Pharmaceutical Industries and Associations (EFPIA) report published earlier this year, for example, compared the timelines of six regulatory agencies between 2011 and 2020. Accelerating safe access.

Safety 93
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. But from a safety point of view, observational studies can be more representative of the population the drug will serve. Meta-analyses contributed least frequently (31.4

Medicine 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Hip Innovation Technology Announces Initiation of FDA Approved Investigational Device Exemption Study

Legacy MEDSearch

The IDE Study is being conducted to determine the safety and effectiveness of the HIT Reverse HRS in Primary Total Hip Arthroplasty (THA). Safety will be assessed through the collection of device-related adverse events and patient quality of life metrics. About Hip Innovation Technology, LLC.

FDA 98
article thumbnail

Three Steps to Hitting Your MLR Targets in 2021 

Clarify Health

Prior to 2011 when the Affordable Care Act (ACA) was passed, many insurance companies were spending a large portion of premium dollars on administrative costs and profits. Health plans should prioritize high-value providers to include in their network based on case-mix adjusted clinical, quality and cost-efficiency scores.

article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

Caregiver observations of the patient experience over the progression of the disease may inform the safety and efficacy of a particular therapeutic. The FDA has studied the importance of caregivers to drug development and regulatory decision-making. Findings note that caregivers are a vital source of information. Sunny White. February 2019.

Pharma 98
article thumbnail

UroMems Announces First-Ever Smart Artificial Urinary Sphincter Implant in a Female Patient

Legacy MEDSearch

This first-in-female procedure was approved by the National Agency for the Safety of Medicines and Health Products (or ANSM, the French equivalent to the U.S. Food and Drug Administration). “It’s magic,” the patient stated, as the first woman to activate the novel UroActive device.

article thumbnail

Using RWE in rare disease drug development: effective innovations with historical controls

European Pharmaceutical Review

11 have recently conducted an analysis of international HTA submissions from 2011-2019 to determine the acceptability of single arm clinical studies and ECs as part of the drug reimbursement process. He is a member of the EMEA’s European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ( www.encepp.eu ). Patel et al.